News Sentiment

CTXR sentiment intelligence

Citius Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 68 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.50 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-14.9% over one week, -9.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -14.9% Price reacting lower
Trend fit Trend inactive -9.3% over four weeks
Fair value -94.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 49
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
PR Newswire 11
TradingView 11
Market source 10
TradingKey 6
Stock Titan 4
Simply Wall Street 2
Moomoo 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 21
Analyst action 8
Deals and strategy 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 68
Simply Wall Street Direct company coverage

Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is projected to reach breakeven within just over a year, with analysts forecasting a final loss in 2026 before generating positive profits of US$27m in 2027. This profitability hinges on an average annual growth rate of 56%. The company,

Tone
Positive 70/100
Event
Market update
Published
28 May 2026 11:39
Source
Simply Wall Street
Financial Times Direct company coverage

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting – Company Announcement - FT.com

Citius Oncology announced that data from an investigator-initiated Phase 1 study of LYMPHIR® in combination with pembrolizumab for relapsed/refractory gynecologic malignancies will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study sho

Tone
Positive 72/100
Event
Market update
Published
26 May 2026 11:40
Source
Financial Times
Stock Titan Direct company coverage

Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants

Citius Pharmaceuticals (NASDAQ: CTXR) has registered 5.43 million shares for resale, stemming from the potential exercise of common and placement agent warrants. While the company will not receive proceeds directly from these resales, it could gain up to $4.8 million if all warra

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 20:38
Source
Stock Titan
Insider Monkey Direct company coverage

5 Best Rated Penny Stocks to Buy According to Wall Street Analysts

This article highlights Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) as one of the top-rated penny stocks by Wall Street analysts. H.C. Wainwright initiated coverage with a Buy rating and a $4 price target, citing encouraging early commercial launch metrics for the company's lead t

Tone
Positive 70/100
Event
Analyst action
Published
22 May 2026 02:09
Source
Insider Monkey
GuruFocus Direct company coverage

CTXR Assumes Buy Rating by HC Wainwright & Co. -- Price Target at $4.00

HC Wainwright & Co. has initiated coverage on Citius Pharmaceuticals (CTXR) with a Buy rating and a $4.00 price target, suggesting significant upside from its current price of $0.5455. The company, focused on oncology and anti-infectives with its product LYMPHIR, has a GF Score™

Tone
Positive 76/100
Event
Analyst action
Published
19 May 2026 05:08
Source
GuruFocus
Moomoo Direct company coverage

Citius Pharmaceuticals Price Target Announced at $4.00/Share by HC Wainwright & Co.

HC Wainwright & Co. has set a price target of $4.00 per share for Citius Pharmaceuticals (NASDAQ: CTXR). This target suggests a potential upside for the stock from its current trading levels. This announcement is likely to be of interest to investors tracking pharmaceutical secto

Tone
Positive 77/100
Event
Analyst action
Published
18 May 2026 19:40
Source
Moomoo